Jessica Burket - Christopher Newport University

Directory



Jessica A. Burket

Department of Molecular Biology and Chemistry - Neuroscience Program

Jessica Burket

Assistant Professor

Forbes Hall 1047
(757) 594-8743
jessica.burket@cnu.edu

Education

  • Ph D in Biomedical Sciences, Eastern Virginia Medical School
  • MS in Biomedical Sciences, Eastern Virginia Medial School
  • BS in Psychology, Saint Francis University

Teaching

Principles of Biology I
Neurobiology
Senior Seminar in Neuroscience

Research

My research interests include studying the neuropsychopharmacology and neurobiological mechanisms of psychiatric and neurodevelopmental disorders, such as schizophrenia and autism spectrum disorder.

Selected Accomplishments

  • Journal Article, Academic Journal
    (2022). From Mouse to Man: N-Methyl-d-Aspartic Acid Receptor Activation as a Promising Pharmacotherapeutic Strategy for Autism Spectrum Disorders. Medical Clinics of North America.
  • Journal Article, Academic Journal
    (2022). Targeted NMDA Receptor Interventions for Autism: Developmentally Determined Expression of GluN2B and GluN2A-Containing Receptors and Balanced Allosteric Modulatory Approaches. Biomolecules. Volume, 12. Issue, 2. Pages, 181.
  • Journal Article, Academic Journal
    (2021). Disrupted copper homeostasis: Pathogenic factor in autism spectrum disorder and side effect of valproic acid. Personalized Medicine in Psychiatry. Volume, 29-30. Pages, 100087.
  • Journal Article, Academic Journal
    (2021). Perineuronal Nets and Metal Cation Concentrations in the Microenvironments of Fast-Spiking, Parvalbumin-Expressing GABAergic Interneurons: Relevance to Neurodevelopment and Neurodevelopmental Disorders. Biomolecules. Volume, 11. Issue, 8. Pages, 1235.
  • Journal Article, Academic Journal
    (2021). Exposure to Low (≤10 cGy) Doses of 4He Particles Leads to Increased Social Withdrawal and Loss of Executive Function Performance.. Radiation research.
  • Case Study, Academic Journal or Book
    (2021). A DeNovo Missense Variant of SCN2A; Implications and Limitations for Understanding Clinical Phenotype and Treatment Recommendations. Clinical Neuropharmacology.
  • Journal Article, Academic Journal
    (2021). Psychotropic medication use for adults and older adults with intellectual disability; selective review, recommendations and future directions. Prog Neuropsychopharmacol Biol Psychiatry. Volume, 104.
  • Book, Chapter in Scholarly Book-New
    (2020). An Evolving Therapeutic Rationale for Targeting the α7 Nicotinic Acetylcholine Receptor in Autism Spectrum Disorder. Springer, Cham. Volume, 45. Pages, 167-208.
  • Shane Potters, Benjamin Goodman, Colleen Neff, Lily Kowalski, Abigail Bunting, Scott Burden, Nicholas Truver, Austin Thompson, Shania Smaw, Daniel Calvano, Jordan Sanchez, Darlene Mitrano, James Bogenpohl, Jessica Burket, Society for Neuroscience, "Examining behavioral and molecular effects after sub-chronic administration of an NMDA receptor partial agonist in a 22q11.2," Washington, DC. (2023)
  • Aidan Rucker, Sarah Jones, Stephen Deutsch, Jessica Burket, Society for Neuroscience, "Transcriptomic profiling and bioinformatic analysis reveals modulation of mTOR-associated genes following glycine type 1 tran," Chicago, IL. (2021)
  • Jessica Burket, "Role of the NLRP3 Inflammasome in Mediating Microglial Activation and Development of Neuropsychiatric Symptoms Induced by HIV," Sponsored by NIH- National Institute on Drug Abuse (NIDA)
  • Jessica Burket, "Behavioral and Molecular Characterization of Adolescent Df(h22q11)/+ Mice," Sponsored by Taconic Biosciences
quick edit report a problem